{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wei Y"],"funding":["Medical Research Council","wellcome trust","Wellcome Trust","Academy of Medical Sciences"],"pagination":["385"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8487486"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<h4>Objective</h4>The objective of this study was to employ ensemble clustering and tree-based risk model approaches to identify interactions between clinicogenomic features for colorectal cancer using the 100,000 Genomes Project.<h4>Results</h4>Among the 2211 patients with colorectal cancer (mean age of diagnosis: 67.7; 59.7% male), 16.3%, 36.3%, 39.0% and 8.4% had stage 1, 2, 3 and 4 cancers, respectively. Almost every patient had surgery (99.7%), 47.4% had chemotherapy, 7.6% had radiotherapy and 1.4% had immunotherapy. On average, tumour mutational burden (TMB) was 18 mutations/Mb and 34.4%, 31.3% and 25.7% of patients had structural or copy number mutations in KRAS, BRAF and NRAS, respectively. In the fully adjusted Cox model, patients with advanced cancer [stage 3 hazard ratio (HR)  ="],"journal":["BMC research notes"],"pubmed_title":["Application of ensemble clustering and survival tree analysis for identifying prognostic clinicogenomic features in patients with colorectal cancer from the 100,000 Genomes Project."],"pmcid":["PMC8487486"],"funding_grant_id":["SBF006\\1084","204841/Z/16/Z","HDR-9004","MR/S006753/1"],"pubmed_authors":["Papachristou N","Savage K","Fowler T","Chan GC","Williams E","Pullinger J","Lopez FJ","Walsh E","Maleady-Crowe F","Genomics England Research Consortium","Lahnstein L","Hubbard TJP","Welland MJ","Stuckey A","Chang WH","Sieghart A","Caulfield MJ","Hamblin A","Mueller M","O'Donovan P","Ambrose JC","Scott RH","Mueller S","Tucci A","Moutsianas L","Bleda M","Leigh SEA","Patch C","Thomas ERA","Brittain H","Jones LJ","Arumugam P","Kasperaviciute D","Henderson S","Pereira MB","Rogers T","Wei Y","Boardman-Pretty F","Kayikci M","Thompson SR","Murugaesu N","Leong IUS","Kousathanas A","Witkowska K","Tanguy M","Lai AG","Smith SC","Jackson R","Giess A","Rendon A","Sosinsky A","Perez-Gil D","Need AC","Sawant K","Boustred CR","Siddiq A","Odhams CA","Rahim T","Wood SM"],"additional_accession":[]},"is_claimable":false,"name":"Application of ensemble clustering and survival tree analysis for identifying prognostic clinicogenomic features in patients with colorectal cancer from the 100,000 Genomes Project.","description":"<h4>Objective</h4>The objective of this study was to employ ensemble clustering and tree-based risk model approaches to identify interactions between clinicogenomic features for colorectal cancer using the 100,000 Genomes Project.<h4>Results</h4>Among the 2211 patients with colorectal cancer (mean age of diagnosis: 67.7; 59.7% male), 16.3%, 36.3%, 39.0% and 8.4% had stage 1, 2, 3 and 4 cancers, respectively. Almost every patient had surgery (99.7%), 47.4% had chemotherapy, 7.6% had radiotherapy and 1.4% had immunotherapy. On average, tumour mutational burden (TMB) was 18 mutations/Mb and 34.4%, 31.3% and 25.7% of patients had structural or copy number mutations in KRAS, BRAF and NRAS, respectively. In the fully adjusted Cox model, patients with advanced cancer [stage 3 hazard ratio (HR)  =","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-06-01T00:55:28.46Z","creation":"2025-06-01T00:55:28.46Z"},"accession":"S-EPMC8487486","cross_references":{"pubmed":["34600575"],"doi":["10.1186/s13104-021-05789-0"]}}